Lanreotid Amdipharm

Lanreotide acetate, the active ingredient in Lanreotid Amdipharm, is a somatostatin analog presented as a subcutaneous formulation for subcutaneous use. It is employed to lower excess growth hormone in adults with acromegaly and to control hormone‑secreting neuroendocrine tumors.

GNH USA supplies Lanreotid Amdipharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The product meets European Union quality standards and is distributed under strict temperature‑controlled conditions. Our global logistics network ensures timely delivery to clinical sites across continents, supporting patient access to specialized therapies.

Lanreotide acetate is a somatostatin analog used in conditions driven by excess hormone secretion. - Acromegaly: reduces serum growth hormone and IGF‑1 levels, helping control disease activity in adults. - Gastroenteropancreatic neuroendocrine tumors: suppresses hormone secretion and can stabilize tumor growth in patients with functional NETs. - Carcinoid syndrome: alleviates flushing and diarrhea associated with hormone‑producing tumors.

Lanreotide acetate may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Injection site pain or erythema - Diarrhea - Nausea - Abdominal discomfort - Headache - Flushing

Serious or Rare Side Effects: - Gallbladder sludge or gallstones - Hyperglycemia or new‑onset diabetes - Acute pancreatitis - Severe allergic reactions (anaphylaxis, angioedema) - Cardiac arrhythmias - Severe hepatic dysfunction

Before initiating lanreotide therapy, several safety considerations should be reviewed. - Glucose monitoring: assess blood sugar levels as treatment may worsen hyperglycemia. - Gallbladder evaluation: screen for gallstones or biliary disease before use. - Cardiac assessment: monitor for arrhythmias in patients with known heart conduction issues. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks; discuss with obstetric specialist. - Renal/hepatic function: adjust therapy in patients with significant impairment. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lanreotide can interact with other medicines, affecting its efficacy or safety profile.

Major Interactions (Avoid): - Cytochrome P450 inhibitors (e.g., ketoconazole): may increase lanreotide plasma concentrations. - Co‑administration with other somatostatin analogues: additive hormonal suppression can lead to severe hypoglycemia.

Moderate Interactions (Monitor Closely): - Antidiabetic agents: monitor glucose as lanreotide may alter glycemic control. - Anticoagulants (e.g., warfarin): observe INR values for potential changes. - Diuretics: watch electrolyte balance, especially potassium. - Thyroid hormone replacement: assess thyroid function tests periodically.